At a glance
ClinicalIndex Comparison RecordN/ACompleted· 63 enrolled
Drug / intervention
Zentiva® +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double-blind, Randomized, Parallel Group, Placebo Controlled Clinical Trial to Evaluate the Effects of Atomoxetine on Impulsivity in Behavioral Laboratory Tasks in Adult ADHD Patients
In Brief
A clinical study evaluating Zentiva® and Placebo for Attention Deficit Hyperactivity Disorder. Completed, enrolled 63 participants across 5 sites.
Detailed Summary
The primary objectives are to investigate the effect of atomoxetine on impulsivity after single dose and at steady state measured by the total score of Barrett Impulsiveness Scale version 11 (BIS-11) and Short Urgency, Perseverance, Premeditation, and Sensation Seeking-Positive Urgency Impulsive Behavior Scale (S-UPPS-P) Impulsive Behavior Scale. The secondary objective is to evaluate the safety of atomoxetine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Hyperactivity Disorder
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
2023202420252026
First PostedMar 2022
Enrollment StartSep 2023
Primary CompletionOct 2024
Study CompletionOct 2024
TodayJul 2026
First PostedMar 14, 2022
Enrollment StartSep 14, 2023
Primary CompletionOct 23, 2024
Study CompletionOct 30, 2024
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 4.3 years ago
Interventions
Zentiva®drug
Zentiva®, oral, tablet
Placebodrug
Placebo, oral, tablet